stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) EBITDA
Lakefront Biotherapeutics - Sponsored ADR's EBITDA for fiscal 2025 was $397.0M, compared with −$154.6M in fiscal 2024. Over the twelve months to 31 March 2026 it was −$416.8M. Over the past ten years it has ranged from −$212.8M (fiscal 2022) to $428.7M (fiscal 2019); the current reading is higher than 91% of that period. Lakefront Biotherapeutics - Sponsored ADR ranks 568th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $397.0M | — |
| FY2024 | −$154.6M | — |
| FY2023 | −$48.3M | — |
| FY2022 | −$212.8M | — |
| FY2021 | −$154.9M | — |
| FY2020 | −$182.7M | — |
| FY2019 | $428.7M | — |
| FY2018 | −$46.9M | — |
| FY2017 | −$96.7M | — |
| FY2016 | −$8.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Mar 2026 | −$74.6M | — |
| Mar 2025 | −$167.2M | — |
| Mar 2024 | −$36.0M | — |
| Dec 2022 | −$139.0M | — |
| 25 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| SEPN Septerna, Inc. compare | −$41.9M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| ZYME Zymeworks Inc. compare | −$146.1M |
| IMNM Immunome, Inc. compare | −$268.3M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | −$416.8M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement